Genable Technologies Ltd.

Genable Technologies Ltd., a privately held, venture-backed biopharmaceutical company based in Dublin (Ireland), is developing novel gene medicines to treat "dominant" inherited diseases based on the groundbreaking work of Prof. Jane Farrar, Dr. Paul Kenna, and Prof. Peter Humphries.Genable utilizes well-established, clinically safe and effective AAV vectors to express RNA interference (RNAi) molecules that suppress the expression of both mutant and normal gene copies and replace them with subtly altered genes that are resistant to suppression but still encode normal wild-type proteins.The combination of Suppression and Replacement (S&R) overcomes the significant hurdle of mutation variability in dominant diseases by eliminating the need to target specific mutations across multiple conditions. Genable's technology is protected by a broad portfolio of issued patents and pending patent applications in the US, EU, and globally.